search
Back to results

Evaluate the Efficacy and Safety of Different Doses of Edaravone Dexborneol Concentrated Solution for Injection Combined With Conventional Medical Therapy in the Treatment of Patients With Cerebral Hemorrhage

Primary Purpose

Subjects With Cerebral Hemorrhage

Status
Recruiting
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Synbixin/Placebo
Sponsored by
Simcere Pharmaceutical Co., Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Subjects With Cerebral Hemorrhage

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: the subject himself or her legal representative has signed the informed consent form; aged ≥ 18 years and ≤ 80 years, male or female; clinical diagnosis of cerebral hemorrhage, in line with the Chinese Medical Association Neurology Score issued by the "Key Points in the Diagnosis of Various Major Cerebrovascular Diseases in China 2019" cerebral hemorrhage diagnostic criteria [1]; the bleeding center site is located in the basal ganglia; intracranial hematoma volume ≤ 30 ml; NIHSS score at enrollment total score ≥ 6 points and ≤ 20 points, and the sum of items 5 and 6 ≥ 2 points; coma degree is mild to moderate, Glasgow Coma Scale (GCS) ≥ 9 points; the time from the onset of this stroke to the start of study treatment is 6 to 24 hours (subjects who sign the informed consent form should receive study treatment as soon as possible, some subjects meet the criteria during the screening period, more than 24 hours when starting study treatment, this patient should terminate the study treatment); mRS score of 0 or 1 before onset. Exclusion Criteria: allergic to edaravone, dextromethorphan or contained excipients; stroke within the past 3 months; other concomitant sites of hematoma volume > 5ml, or the need for external ventricular drainage of patients with intraventricular hemorrhage; patients with obstructive hydrocephalus; drugs, vascular structural damage or coagulation disorders caused by cerebral hemorrhage; vital signs unstable, suspected cerebral hernia, deep coma or anisocoria and other critical manifestations; after this onset has been applied edaravone or dextromethorphan components (such as edaravone injection, Angong Niuhuang pills, Xingnaojing, etc.) of drugs, or has applied a total of more than 2 times the daily recommended dose of the instructions of the following drugs: citicoline, oxiracetam, piracetam, ulinastatin; planned surgical evacuation of hematoma, including: craniotomy hematoma evacuation, minimally invasive surgery and decompressive craniectomy; ALT or AST > 2.0 × ULN or previously known liver disease, such as acute hepatitis, chronic active hepatitis, cirrhosis, etc., previously known kidney disease, renal insufficiency, serum creatinine > 1.5 × ULN or creatinine clearance < 50 mL/min; Suffering from other bleeding disorders, such as thrombocytopenic purpura, bleeding tendency caused by vascular injury, hemophilia and other coagulation disorders, gastrointestinal ulcers, urinary tract bleeding, hemoptysis, etc.; Presence of severe, progressive, or uncontrolled symptoms of renal, hepatic, hematological, gastrointestinal, pulmonary, cardiovascular, neurological, or cerebral disease that, in the opinion of the investigator, place the subject at unacceptable risk by participating in this study; With severe active bacterial or viral infection; Concurrent malignancy or ongoing anti-tumor therapy; With severe systemic disease, expected survival < 90 days; Patients with severe mental disorders and dementia; Patients who are pregnant, lactating and planning pregnancy; Reasons for other investigators' unsuitability to participate in this trial.

Sites / Locations

  • The First Affiliated Hospital, Sun Yat-sen UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Part A 1 - Subjects with cerebral hemorrhage (Synbixin 37.5 mg; placebo group )

Part A 2 - Subjects with cerebral hemorrhage ( Synbixin 62.5 mg; placebo group )

Part B - Subjects with cerebral hemorrhage ( Synbixin TBD mg; placebo group )

Arm Description

Outcomes

Primary Outcome Measures

Incidence of serious adverse events (SAEs) up to 90 days after the first dose of treatment

Secondary Outcome Measures

Incidence of deaths up to 90 days after the first dose of treatment
Proportion of subjects with AEs, AEs leading to dose interruption or discontinuation, AEs related to study drug, AEs of special interest (AESls), and with abnormal vital signs, abnormal physical examination findings and abnormal laboratory tests results
Proportion of subjects with modified Rankin Score (mRS) 0-2, which assesses the degree of disability or dependence in daily activities, with scores ranging from 0 (no symptoms) to 6 (death), at 90 days after the first dose of treatment
Proportion of subjects with modified Rankin Score (mRS) 0-1, which assesses the degree of disability or dependence in daily activities, with scores ranging from 0 (no symptoms) to 6 (death), at 90 days after the first dose of treatment
Distribution of subjects with modified Rankin Score (mRS), which assesses the degree of disability or dependence in daily activities, with scores ranging from 0 (no symptoms) to 6 (death), at 14, 30, 90 days after the first dose of treatment
Distribution of subjects with Glasgow Outcome Score (GOS), which measures functional outcome, with scores ranging from I (Dead) to V (Good Recovery), at 14, 30, 90 days after the first dose of treatment
Change from baseline in National Institutes of Health Stroke Scale (NIHSS), which quantifies the impairment caused by a stroke, with scores ranging from 0 (no stroke symptoms) to 42 (the most severe stroke)
Proportion of subjects with National Institutes of Health Stroke Scale (NIHSS) 0-2, which quantifies the impairment caused by a stroke, with scores ranging from 0 (no stroke symptoms) to 42 (the most severe stroke)
Proportion of subjects with Barthel index (BI), which measures a person's ability to complete activities of daily, with scores ranging from 0 (fully dependent) to 20 (fully independent), at 90 days after the first dose of treatment
Imaging endpoints:Change from baseline in perihematomal edema volume (PHEv) and hematoma volume (HV) in milliliters
Imaging endpoints:Change from baseline in edema extension distance (EED) in millimetres c) Change from baseline in relative perihematomal edema (PHEv/Hv) in odds ratio
Imaging endpoints: Change from baseline in relative perihematomal edema (PHEv/Hv) in odds ratio
Plasma pharmacokinetic endpoints: Cmax: maximum observed plasma concentration for edaravone and dexborneol
Plasma pharmacokinetic endpoints: Tmax: time to reach the maximum plasma concentration (Cmax) for edaravone and dexborneol
Plasma pharmacokinetic endpoints: AUC(0-inf): area under the plasma concentration-time curve from time 0 to infinity for edaravone and dexborneol
Plasma biomarker endpoints: a) Change from baseline in white blood cell count (WBC) in 109/L; b) Change from baseline in C-reactive protein (CRP), Thioredoxin (TRX) and matrix metalloproteinases (MMP) in mg/L

Full Information

First Posted
June 24, 2023
Last Updated
July 11, 2023
Sponsor
Simcere Pharmaceutical Co., Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT05953103
Brief Title
Evaluate the Efficacy and Safety of Different Doses of Edaravone Dexborneol Concentrated Solution for Injection Combined With Conventional Medical Therapy in the Treatment of Patients With Cerebral Hemorrhage
Official Title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of Different Doses of Edaravone Dexborneol Concentrated Solution for Injection Combined With Conventional Medical Therapy in the Treatment of Patients With Cerebral Hemorrhage
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 3, 2023 (Actual)
Primary Completion Date
March 31, 2025 (Anticipated)
Study Completion Date
June 30, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Simcere Pharmaceutical Co., Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The SIM0355-201 trial is a multicenter, randomized, double-blind, placebo-controlled exploratory clinical trial with the main study objective of evaluating the safety and tolerability of different doses of Edaravone Dexborneol concentrate for injection combined with conventional medical therapy in patients with cerebral hemorrhage. The subject had a clinical diagnosis of cerebral hemorrhage, within 6-24 hours from stroke onset to start of study treatment, with the bleeding site in basal ganglia and a hematoma volume ≤ 30 ml at the bleeding site. The trial was divided into two periods (Period A and Period B), with Period A being a dose escalation period divided into two dose levels: the first dose level group (Dose 1 group: Synbixin 37.5 mg; placebo group) and the second dose level group (Dose 2 group: Synbixin 62.5 mg; placebo group).
Detailed Description
The SIM0355-201 trial is a multicenter, randomized, double-blind, placebo-controlled exploratory clinical trial with the main study objective of evaluating the safety and tolerability of different doses of Edaravone Dexborneol concentrate for injection combined with conventional medical therapy in patients with cerebral hemorrhage. The subject had a clinical diagnosis of cerebral hemorrhage, within 6-24 hours from stroke onset to start of study treatment, with the bleeding site in basal ganglia and a hematoma volume ≤ 30 ml at the bleeding site. The trial was divided into two periods (Period A and Period B), with Period A being a dose escalation period divided into two dose levels: the first dose level group (Dose 1 group: Synbixin 37.5 mg; placebo group) and the second dose level group (Dose 2 group: Synbixin 62.5 mg; placebo group). Safety was assessed unblinding after the end of study treatment for all subjects in the first dose level group and escalated to the second dose level if the "safe dose" criterion was met, otherwise the trial was terminated; safety was assessed unblinding after the end of study treatment for all subjects in the second dose level group and the 62.5 mg dose level was selected to enter Stage B if the "safe dose" criterion was met, otherwise the 37.5 mg dose level was selected to enter Stage B.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Subjects With Cerebral Hemorrhage

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
380 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Part A 1 - Subjects with cerebral hemorrhage (Synbixin 37.5 mg; placebo group )
Arm Type
Experimental
Arm Title
Part A 2 - Subjects with cerebral hemorrhage ( Synbixin 62.5 mg; placebo group )
Arm Type
Experimental
Arm Title
Part B - Subjects with cerebral hemorrhage ( Synbixin TBD mg; placebo group )
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Synbixin/Placebo
Intervention Description
Synbixin/Placebo
Primary Outcome Measure Information:
Title
Incidence of serious adverse events (SAEs) up to 90 days after the first dose of treatment
Time Frame
up to 90 days after the first dose of treatment
Secondary Outcome Measure Information:
Title
Incidence of deaths up to 90 days after the first dose of treatment
Time Frame
up to 90 days after the first dose of treatment
Title
Proportion of subjects with AEs, AEs leading to dose interruption or discontinuation, AEs related to study drug, AEs of special interest (AESls), and with abnormal vital signs, abnormal physical examination findings and abnormal laboratory tests results
Time Frame
up to 90 days after the first dose of treatment
Title
Proportion of subjects with modified Rankin Score (mRS) 0-2, which assesses the degree of disability or dependence in daily activities, with scores ranging from 0 (no symptoms) to 6 (death), at 90 days after the first dose of treatment
Time Frame
at 90 days after the first dose of treatment
Title
Proportion of subjects with modified Rankin Score (mRS) 0-1, which assesses the degree of disability or dependence in daily activities, with scores ranging from 0 (no symptoms) to 6 (death), at 90 days after the first dose of treatment
Time Frame
at 90 days after the first dose of treatment
Title
Distribution of subjects with modified Rankin Score (mRS), which assesses the degree of disability or dependence in daily activities, with scores ranging from 0 (no symptoms) to 6 (death), at 14, 30, 90 days after the first dose of treatment
Time Frame
at 14, 30, 90 days after the first dose of treatment
Title
Distribution of subjects with Glasgow Outcome Score (GOS), which measures functional outcome, with scores ranging from I (Dead) to V (Good Recovery), at 14, 30, 90 days after the first dose of treatment
Time Frame
at 14, 30, 90 days after the first dose of treatment
Title
Change from baseline in National Institutes of Health Stroke Scale (NIHSS), which quantifies the impairment caused by a stroke, with scores ranging from 0 (no stroke symptoms) to 42 (the most severe stroke)
Time Frame
at 14, 30, 90 days after the first dose of treatment
Title
Proportion of subjects with National Institutes of Health Stroke Scale (NIHSS) 0-2, which quantifies the impairment caused by a stroke, with scores ranging from 0 (no stroke symptoms) to 42 (the most severe stroke)
Time Frame
at 14, 30, 90 days after the first dose of treatment
Title
Proportion of subjects with Barthel index (BI), which measures a person's ability to complete activities of daily, with scores ranging from 0 (fully dependent) to 20 (fully independent), at 90 days after the first dose of treatment
Time Frame
at 90 days after the first dose of treatment
Title
Imaging endpoints:Change from baseline in perihematomal edema volume (PHEv) and hematoma volume (HV) in milliliters
Time Frame
at 3, 7, 14 days after the first dose of treatment
Title
Imaging endpoints:Change from baseline in edema extension distance (EED) in millimetres c) Change from baseline in relative perihematomal edema (PHEv/Hv) in odds ratio
Time Frame
at 3, 7, 14 days after the first dose of treatment
Title
Imaging endpoints: Change from baseline in relative perihematomal edema (PHEv/Hv) in odds ratio
Time Frame
at 3, 7, 14 days after the first dose of treatment
Title
Plasma pharmacokinetic endpoints: Cmax: maximum observed plasma concentration for edaravone and dexborneol
Time Frame
1 hour pre-dose and 1, 2 hour post-dose at 3, 14 days after the first dose of treatment
Title
Plasma pharmacokinetic endpoints: Tmax: time to reach the maximum plasma concentration (Cmax) for edaravone and dexborneol
Time Frame
1 hour pre-dose and 1, 2 hour post-dose at 3, 14 days after the first dose of treatment
Title
Plasma pharmacokinetic endpoints: AUC(0-inf): area under the plasma concentration-time curve from time 0 to infinity for edaravone and dexborneol
Time Frame
1 hour pre-dose and 1, 2 hour post-dose at 3, 14 days after the first dose of treatment
Title
Plasma biomarker endpoints: a) Change from baseline in white blood cell count (WBC) in 109/L; b) Change from baseline in C-reactive protein (CRP), Thioredoxin (TRX) and matrix metalloproteinases (MMP) in mg/L
Time Frame
at 3, 7, 14 days after the first dose of treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: the subject himself or her legal representative has signed the informed consent form; aged ≥ 18 years and ≤ 80 years, male or female; clinical diagnosis of cerebral hemorrhage, in line with the Chinese Medical Association Neurology Score issued by the "Key Points in the Diagnosis of Various Major Cerebrovascular Diseases in China 2019" cerebral hemorrhage diagnostic criteria [1]; the bleeding center site is located in the basal ganglia; intracranial hematoma volume ≤ 30 ml; NIHSS score at enrollment total score ≥ 6 points and ≤ 20 points, and the sum of items 5 and 6 ≥ 2 points; coma degree is mild to moderate, Glasgow Coma Scale (GCS) ≥ 9 points; the time from the onset of this stroke to the start of study treatment is 6 to 24 hours (subjects who sign the informed consent form should receive study treatment as soon as possible, some subjects meet the criteria during the screening period, more than 24 hours when starting study treatment, this patient should terminate the study treatment); mRS score of 0 or 1 before onset. Exclusion Criteria: allergic to edaravone, dextromethorphan or contained excipients; stroke within the past 3 months; other concomitant sites of hematoma volume > 5ml, or the need for external ventricular drainage of patients with intraventricular hemorrhage; patients with obstructive hydrocephalus; drugs, vascular structural damage or coagulation disorders caused by cerebral hemorrhage; vital signs unstable, suspected cerebral hernia, deep coma or anisocoria and other critical manifestations; after this onset has been applied edaravone or dextromethorphan components (such as edaravone injection, Angong Niuhuang pills, Xingnaojing, etc.) of drugs, or has applied a total of more than 2 times the daily recommended dose of the instructions of the following drugs: citicoline, oxiracetam, piracetam, ulinastatin; planned surgical evacuation of hematoma, including: craniotomy hematoma evacuation, minimally invasive surgery and decompressive craniectomy; ALT or AST > 2.0 × ULN or previously known liver disease, such as acute hepatitis, chronic active hepatitis, cirrhosis, etc., previously known kidney disease, renal insufficiency, serum creatinine > 1.5 × ULN or creatinine clearance < 50 mL/min; Suffering from other bleeding disorders, such as thrombocytopenic purpura, bleeding tendency caused by vascular injury, hemophilia and other coagulation disorders, gastrointestinal ulcers, urinary tract bleeding, hemoptysis, etc.; Presence of severe, progressive, or uncontrolled symptoms of renal, hepatic, hematological, gastrointestinal, pulmonary, cardiovascular, neurological, or cerebral disease that, in the opinion of the investigator, place the subject at unacceptable risk by participating in this study; With severe active bacterial or viral infection; Concurrent malignancy or ongoing anti-tumor therapy; With severe systemic disease, expected survival < 90 days; Patients with severe mental disorders and dementia; Patients who are pregnant, lactating and planning pregnancy; Reasons for other investigators' unsuitability to participate in this trial.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yi Wang
Phone
15805160455
Email
wangyi4@simcere.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Xiaonan Yao
Organizational Affiliation
Simcere Pharmaceutical Co., Ltd
Official's Role
Study Director
Facility Information:
Facility Name
The First Affiliated Hospital, Sun Yat-sen University
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510080
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jinsheng Zeng, Doctor
Phone
020-87755766-8293
Email
zengjs@pub.guangzhou.gd.cn

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Evaluate the Efficacy and Safety of Different Doses of Edaravone Dexborneol Concentrated Solution for Injection Combined With Conventional Medical Therapy in the Treatment of Patients With Cerebral Hemorrhage

We'll reach out to this number within 24 hrs